



Supplementary Figure 1. *Stat1^{β/β}*, but not *Stat1^{α/α}*, mice show impaired liver NK cell maturation. (**A**, **B**) The abundance of NK cells (CD3ε⁻NK1.1⁺NKp46⁺CD49b⁺) (**A**) and NK cell maturation subsets (CD27⁻CD11b⁻, CD27⁺CD11b⁻, CD27⁺CD11b⁺, CD27⁺CD11b⁺) (**B**) in livers from *WT*, *Stat1^{-/-}*, *Stat1^{α/α}* and *Stat1^{β/β}* mice were analyzed. Mean percentages \pm SEM (n = 6-9) from three experiments (**A**, **B**) are shown. **p* < 0.05; ***p* < 0.01; ****p* < 0.001.



Supplementary Figure 2. The abundance of splenic NK cells is not affected by the lack of type I or type II IFN responsiveness but slightly reduced in the absence of a functional IL-27 receptor. (A-C) The abundance of NK cells (CD3 ϵ ⁻NK1.1⁺) in spleens from *WT*, *Stat1^{β/β} Ifnar1^{-/-}* and *Ifnar1^{-/-}* Stat1^{β/β} (A), *WT* and *II27ra^{-/-}* (B) and *WT*, *Stat1^{β/β}*, *Ifngr1^{-/-}* and *Ifngr1^{-/-}Stat1^{β/β}* mice (C) was determined by flow cytometry. Mean percentages ± SEM of eight (n = 5-18) (A), two (n = 12) (B) and six experiments (n = 10-14) (C) are shown. *p < 0.05.



Supplementary Figure 3. *Stat1^{-/-}* and *Stat1^{β/β}* NK cells produce similar levels of IFN γ upon stimulation with PMA/ionomycin or IL-12/IL-18 compared to *WT* NK cells. (**A-D**) Splenocytes (**A**) and magnetic beads-purified NK cells (**B-D**) from *WT*, *Stat1^{-/-}*, *Stat1^{α/α}* and *Stat1^{β/β}* mice were stimulated with PMA/ionomycin (**A-C**) and IL-12 (5 ng/ml) and IL-18 (25 ng/ml) (**D**) and incubated in the presence (**A**) or absence (**B-D**) of brefeldin A for 5 hours (**A**), 6 hours (**B**) and 21 hours (**C**, **D**). IFN γ production of NK cells was analyzed by intracellular staining and flow cytometry (**A**) or in the cell culture supernatant by ELISA (**B-D**). Mean percentages ± SEM from two experiments (n = 5-6) (**A**) and mean IFN γ concentrations ± SEM from one experiment (n = 3) (**B-D**) are depicted.



Supplementary Figure 4. In the presence of only STAT1β splenocytes have reduced MHC class I surface levels, whereas NK cells have similar inhibitory and activating receptor levels compared to *WT* cells. (A-C) Surface levels of MHC class I molecules on splenic NK cells, T cells, DCs, macrophages and B cells from *WT*, *Stat1*-/- and *Stat1*^{β/β} mice were determined by flow cytometry. Quantitative analysis of surface MHC class I (MHC I) levels (MdFIs) on NK cells (left), T cells (middle) and DCs (right) (A), and on macrophages (left) and B cells (right) (B). Mean MdFIs ± SEM from three experiments (n = 9, A, B left panel and n = 5-8, B right panel). (C) Histograms show one representative sample per genotype of surface MHC class I levels on macrophages (left panel) and B cells (right panel). (D-K) Surface levels of the inhibitory receptors Ly49A (D), Ly49C/I (E), NKG2A/C/E (F) and Ly49G2 (G) and the activating receptors NK1.1 (H), NKp46 (I), NKG2D (J) and Ly49D (K) on splenic NK cells from *WT*, *Stat1*-/-, *Stat1*^{α/α} and *Stat1*^{β/β} mice were analysed by flow cytometry. Mean MdFIs ± SEM from two (n = 5-6) (D-I, K) and three (n = 8) (J) experiments are shown. **p* < 0.05; ***p* < 0.01; ****p* < 0.001.



Supplementary Figure 5. *Stat1^{β/β}* mice have reduced STAT1 levels in splenic DCs, monocytes and macrophages compared to *WT* cells. **(A-C)** Flow cytometry was used to determine STAT1 levels in splenic DCs subsets, monocytes and macrophages from *WT*, *Stat1^{-/-}* and *Stat1^{β/β}* mice. Quantitative analysis of STAT1 in CD8⁺ DCs (left) and CD11b⁺ DCs (right) **(A)** and monocytes (left) and macrophages (right) **(B)**. The average MdFI of STAT1 in *Stat1^{-/-}* cells was subtracted from the MdFI of STAT1 of all samples. Mean MdFIs \pm SEM (n = 6) from two experiments are shown **(A, B)**. **(C)** Histograms of one representative sample per genotype of STAT1 levels in CD8⁺ DCs (left) and CD11b⁺ DCs (right). ****p* < 0.001.



Supplementary Figure 6. IL-15 responsiveness is unaltered in NK cells from *Stat1*^{-/-} and *Stat1*^{\beta/\beta} and *Stat1*^{\beta/\beta} MK cells exhibit normal maturation in *Jak1*^{\beta/\beta}Ncr1Cre bone marrow chimeras. **(A-C)** *WT*, *Stat1*^{-/-} and *Stat1*^{\beta/\beta} mice were treated with PBS or IL-15/IL-15R\alpha for one week. Spleen weight **(A)**, number of splenocytes **(B)** and percentage of NK cells **(C)** were analysed. Mean values \pm SEM of three (n = 9) **(A, B)** and four experiments (n = 10-12) **(C)** are shown. **(D-F)** Splenocytes from *WT*, *Stat1*^{-/-} and *Stat1*^{\beta/\beta} bone marrow chimeric mice and *Jak1*^{\beta/\beta}Ncr1Cre controls were analyzed for the frequency of total NK cells (CD3\varepsilon NK1.1⁺) **(D)**, the maturation subsets CD27⁻CD11b⁺, CD27⁺CD11b⁺ and CD27⁻CD11b⁺ **(E)** and CD11b⁺KLRG1⁺ NK cells **(F)**. Mean percentages \pm SEM of three experiments (n = 6-10) are shown **(D-F)**. **(G)** Splenic NK cells from *WT*, *Stat1*^{-/-}, *Stat1*^{\alpha/\beta} and *Stat1*^{\beta/\beta} mice were FACS-sorted and STAT1 protein levels were determined by Western blot. One representative of two experiments is shown. **(H)** Total STAT1 levels were determined in NK cell maturation subsets (CD27⁻CD11b⁻, CD27⁺CD11b⁺ and CD27⁻CD11b⁺ from *WT*, *Stat1*^{-/-}, *Stat1*^{\alpha/\beta} and *Stat1*^{\beta/\beta} mice by flow cytometry. The average MdFI of STAT1 in *Stat1*^{-/-} cells was subtracted from the MdFI of STAT1 of all samples. Mean MdFIs \pm SEM (n = 6) from two experiments are depicted. **p* < 0.05; ***p* < 0.01; ****p* < 0.001.